• News
  • SAN DIEGO
  • Finance

Isis gains most in 5 years on analyst praise for novel drug

Isis Pharmaceuticals Inc. (Nasdaq: ISIS) rose the most in almost five years after Cowen & Co. analyst Eric Schmidt raised his rating to outperform from neutral based on an experimental therapy's likelihood of becoming a blockbuster.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments

Isis Pharmaceuticals Inc.

Company Website

1896 Rutherford Road
Carlsbad, CA 92008

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
ISIS
40.71
  -1.57  
- 3.71%
1,923,195,000
62.66
22.25

Insider Trade Data

Date Insider Shares Type Value
09/02/2014 O, Neil Patrick R 1,500 Sell $60,660
09/02/2014 O, Neil Patrick R 1,500 Exchange $15,435
09/02/2014 Parshall, B Lynne 11,071 Sell $445,507
09/02/2014 Parshall, B Lynne 11,071 Exchange $112,574
08/27/2014 Bennett, C Frank 5,000 Sell $202,630

Isis Pharmaceuticals Inc. Executive(s):

Stanley Crooke

  • Chief Executive Officer, Founder, President, Chairman

Similar Companies

NAICS - 325414 - Biological Product (except Diagnostic) Manufacturing
SIC - 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Subscribe Today!